CoChat

RNA-based therapies in inherited retinal diseases

Open access
Girach, Aniz, Audo, Isabelle, Birch, David G., Huckfeldt, Rachel M., Lam, Byron L., Leroy, Bart P., Michaelides, Michel, Russell, Stephen R., Sallum, Juliana M.F., Stingl, Katarina, Tsang, Stephen H., Yang, Paul · 2022 · Therapeutic Advances in Ophthalmology
Cited by 36

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Inherited retinal diseases (IRDs) are a genetically and phenotypically heterogeneous group of genetic eye disorders. There are more than 300 disease entities, and together this group of disorders affects millions of people globally and is a frequent cause of blindness or low-vision certification. However, each type is rare or ultra-rare. Characteristically, the impaired vision in IRDs is due to retinal photoreceptor dysfunction and loss resulting from mutation in a gene that codes for a retinal protein. Historically, IRDs have been considered incurable and individuals living with these blinding conditions could be offered only supportive care. However, the treatment landscape for IRDs is beginning to evolve. Progress is being made, driven by improvements in understanding of genotype–phenotype relationships, through advances in molecular genetic testing and retinal imaging. Alongside this expanding knowledge of IRDs, the current era of precision medicine is fueling a growth in targeted therapies. This has resulted in the first treatment for an IRD being approved. Several other therapies are currently in development in the IRD space, including RNA-based therapies, gene-based therapies (such as augmentation therapy and gene editing), cell therapy, visual prosthetics, and optogenetics. RNA-based therapies are a novel approach within precision medicine that have demonstrated success, particularly in rare diseases. Three antisense oligonucleotides (AONs) are currently in development for the treatment of specific IRD subtypes. These RNA-based therapies bring several key advantages in the setting of IRDs, and the potential to bring meaningful vision benefit to individuals living with inherited blinding disorders. This review will examine the increasing breadth and relevance of RNA-based therapies in clinical medicine, explore the key features that make AONs suitable for treating genetic eye diseases, and provide an overview of the three-leading investigational AONs in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/25158414221134602

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 36

Metadata

Authors
Girach, A., Audo, I., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Stingl, K., Tsang, S. H., & Yang, P.
Venue
Therapeutic Advances in Ophthalmology
Published
2022-01
Volume
14
Pages
25158414221134602-25158414221134602
ISSN
2515-8414 (ISSN-L)
OpenAlex
W4309411718
Cited by
36
References
21
FWCI
2.35
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RNA-based therapies in inherited retinal diseases. https://app.cochat.ai/papers/10.1177/25158414221134602
The paper
Girach, A., Audo, I., Birch, D. G., Huckfeldt, R. M., Lam, B. L., Leroy, B. P., Michaelides, M., Russell, S. R., Sallum, J. M. F., Stingl, K., Tsang, S. H., & Yang, P. (2022). RNA-based therapies in inherited retinal diseases. Therapeutic Advances in Ophthalmology. https://doi.org/10.1177/25158414221134602

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.